5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.

      The Journal of clinical investigation

      Aged, Aged, 80 and over, Alzheimer Disease, metabolism, Animals, Blood-Brain Barrier, DNA-Binding Proteins, antagonists & inhibitors, genetics, Disease Models, Animal, Female, HSP90 Heat-Shock Proteins, Humans, Male, Mice, Molecular Chaperones, Phosphorylation, Protein Folding, RNA, Small Interfering, pharmacology, Serine, Tauopathies, Transcription Factors, Ubiquitin-Protein Ligases, tau Proteins

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A primary pathologic component of Alzheimer's disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau). Expediting the removal of these p-tau species may be a relevant therapeutic strategy. Here we report that inhibition of Hsp90 led to decreases in p-tau levels independent of heat shock factor 1 (HSF1) activation. A critical mediator of this mechanism was carboxy terminus of Hsp70-interacting protein (CHIP), a tau ubiquitin ligase. Cochaperones were also involved in Hsp90-mediated removal of p-tau, while those of the mature Hsp90 refolding complex prevented this effect. This is the first demonstration to our knowledge that blockade of the refolding pathway promotes p-tau turnover through degradation. We also show that peripheral administration of a novel Hsp90 inhibitor promoted selective decreases in p-tau species in a mouse model of tauopathy, further suggesting a central role for the Hsp90 complex in the pathogenesis of tauopathies. When taken in the context of known high-affinity Hsp90 complexes in affected regions of the AD brain, these data implicate a central role for Hsp90 in the development of AD and other tauopathies and may provide a rationale for the development of novel Hsp90-based therapeutic strategies.

          Related collections

          Author and article information

          Journal
          17304350
          1794119
          10.1172/JCI29715

          Comments

          Comment on this article